Home pageInternational biotech eventsOphthalmic Drugs

Ophthalmic Drugs

 

London, UK (November, 28 - 29, 2017)

About Ophthalmic Drugs

SMi Group are thrilled to announce the launch of the Ophthalmic Drugs Conference, being held on the 28-29 November 2017 at the Copthorne Tara Hotel in London, UK.

Ocular disease therapy has seen a surge in innovation in areas ranging from glaucoma to macular degeneration and diabetic retinopathy. As ageing populations grow globally the need for treatment in this field has grown and is expected to reach a figure of $21 billion by the year 2022. – (Source: Business Wire - http://bit.ly/2rlECrh)

Ophthalmic Drugs will gather industry leaders to discuss the latest challenges and changes in the field of ophthalmology. Explore novel approaches to treatment, ocular medical devices, targeted drug delivery technology and real-life challenges to pre-clinical and clinical trials, to deepen your understanding of inherited ocular diseases.

‘By far the most important organs of sense are our eyes. We perceive up to 80 per cent of all impressions by means of our sight. And if other senses such as taste or smell stop working, it's the eyes that best protect us from danger.’ – (Source: Zeiss - http://bit.ly/2tl5iua)

How Will You Benefit?

Network and learn from leading professionals such as:

-          Naj Sharif, Executive Director in R&D, Head, Global Alliances & External Research, Santen Inc

-          Mitchell de Long, Vice President, Chemistry, Aerie Pharmaceuticals

-          Michael Lai, Global Program Medical Director, Novartis

-          Sérgio Leal, Ophthalmologist Director, Global Clinical Leader, Bayer

-          Victor Chong, Global Head of Ophthalmology, Boehringer Ingelheim

-          Amir Shojaei, Vice President Therapeutic Area Head, Ophthalmology, Shire

-          Tomas Navratil, Senior Vice President, Development, Envisia Therapeutics

Visit the website for the full speaker line-up: http://www.ophthalmicdrugs.com/g2b

Some of the featured highlights will include:

-          New approaches to drug delivery to the back of the eye and nanotechnology

-          Discover innovation in diagnostic technology

-          Regulatory keynote on medical devices and human factors

-          Explore various combination products improving health outcomes

-          Exciting insight into stem cell and gene therapy

View the full agenda: http://www.ophthalmicdrugs.com/g2b

Additional Contact Info:

T: +44 (0)20 7827 6000

E: psolanki@smi-online.co.uk

More: http://www.ophthalmicdrugs.com/g2b

OPPI, MPO, EU
Czech Bio

CEBIO

  • CEBIO
  • BC AV CR
  • Budvar
  • CAVD
  • CZBA
  • Eco Tend
  • Envisan Gem
  • Gentrend
  • JAIP
  • Jihočeská univerzita
  • Madeta
  • Forestina
  • ALIDEA

LinkedIn
TOPlist